Phase 2 N=97 Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia
Prostatic Hyperplasia
Primary: Rate of Progression to Prostate Cancer (PCa) — 4; 6 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=7 Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma
Ewing Sarcoma of Bone · Extraosseous Ewing Sarcoma · Peripheral Primitive Neuroectodermal Tumor
Primary: The Occurrence of Limiting Toxicity in an Eligible and Evaluable Patient. — 0 number of toxicities
Phase 2 N=170 Topiramate for Alcohol and Cocaine Dependence
Alcoholism · Cocaine Dependence
Primary: Percent of Participants Abstinent From Cocaine During Last 3 Weeks of 13 Week Trial — 17; 6 Percent of participants — p=0.01
Phase 2 N=10 Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Chronic Myelomonocytic Leukemia · de Novo Myelodysplastic Syndromes · Myelodysplastic Syndromes
Primary: Overall Response Rate (Complete Response, Partial Response, or Hematologic Improvement) Defined by the International Working Group Criteria — 10 percentage of participants
Phase 2 N=447 Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 24 — -0.58; -0.68; -0.76; -0.91 percentage of HbA1c
Phase 2 N=29 Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab
Lymphocytic Leukemia · Mantle Cell Lymphoma
Primary: Overall Response Rate (ORR) — 61 percentage of participants
Phase 2 N=35 Pharmacokinetics, Efficacy and Tolerability of BIA 2-093
Epilepsy
Primary: Maximum Observed Plasma Drug Concentration (Cmax) Post-dose — 6921; 4820; 6382; 16183 ng/mL
Phase 2 N=10 Nitric Oxide, GeNO Nitrosyl Delivery System
Pulmonary Arterial Hypertension
Primary: Number of Participants With Side Effects and/or Adverse Events — 0 participants
Phase 2 N=12 Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
Recurrent Thyroid Cancer · Stage IVA Follicular Thyroid Cancer · Stage IVA Papillary Thyroid Cancer
Primary: Restoration of Radioiodine Uptake in Metastatic Lesions as Demonstrated by Diagnostic Whole-body Scanning After Decitabine Administration — 0 participants
Phase 2 N=38 Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
Adult Non-Hodgkin Lymphoma · Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Nodal Marginal Zone Lymphoma
Primary: Maximum Tolerated Dose of CpG 7909 as Determined Using the Number of Participants With a DLT at Each Dose Level — 0; 1; 0; 1 participants
Phase 2 N=47 Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Detrusor Muscle Hyperactivity
Primary: Daily Incontinence Episode Frequency (IEF) — 4.21; 3.33; 3.23; 4.40 episodes per day — p=0.11
Phase 2 N=279 An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Diabetes Mellitus, Type 2
Primary: Change in HbA1c From Baseline to Week 18 — -0.01; -0.45; -0.61 Percent — p=<0.001
Phase 2 N=30 DFA-02 in Patients Undergoing Colorectal Surgery
Surgical Site Infection
Primary: Number of Patients With Adverse Events, Laboratory, Physical Examination Changes — 23; 6; 5; 2 Participants
Phase 2 N=138 Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer
Neoplasms, Breast
Primary: Number of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Partial Response (PR), as Assessed by the Independent Review Committee…
Phase 2 N=164 Modafinil and Naltrexone to Reduce Cocaine and Alcohol Dependence
Alcohol-Related Disorders · Alcoholism · Cocaine-Related Disorders
Primary: Cocaine Use (Measured by Timeline Follow Back and Urine Screen From Week 2-week 14) — 9.3; 7.2; 10.1; 10.5 number of cocaine negative urine samples